Polo‐like kinase 3 is associated with improved overall survival in cholangiocarcinoma
Benjamin Juntermanns(Essen University Hospital), Christian D. Fingas(Essen University Hospital), Sandra M. Swoboda(Johns Hopkins University), Jan P. Neuhaus(Essen University Hospital), Svenja Sydor(Universitätsklinikum Knappschaftskrankenhaus Bochum), Georgios C. Sotiropoulos(National and Kapodistrian University of Athens), Hideo A. Baba(Essen University Hospital), Derar Jaradat(Essen University Hospital), Wei Meng(Shanghai Medical Information Center), Joachim C. Mertens(GastroZentrum Hirslanden Zürich), Andreas Paul(Essen University Hospital), Zoltán Máthé(Semmelweis University), Gernot M. Kaiser(Essen University Hospital), Ali Canbay(Universitätsklinikum Knappschaftskrankenhaus Bochum)
Cited by 10
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3
|Journal of Clinical Investigation|2004|620
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3
|Journal of Clinical Investigation|2004|598
Non‐alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis
|International Journal of Cancer|2010|520